Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States.
Excellent balance sheet and overvalued.
Share Price & News
How has Gossamer Bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GOSS's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GOSS underperformed the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: GOSS underperformed the US Market which returned 7.1% over the past year.
Price Volatility Vs. Market
How volatile is Gossamer Bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StShould You Be Worried About Insider Transactions At Gossamer Bio, Inc. (NASDAQ:GOSS)?
3 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Gossamer Bio, Inc.'s (NASDAQ:GOSS) Shareholder Register?
5 months ago | Simply Wall StRead This Before Buying Gossamer Bio, Inc. (NASDAQ:GOSS) Shares
Is Gossamer Bio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GOSS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GOSS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GOSS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: GOSS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GOSS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GOSS is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.7x).
How is Gossamer Bio forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GOSS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GOSS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GOSS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if GOSS's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if GOSS's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GOSS's Return on Equity is forecast to be high in 3 years time
How has Gossamer Bio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GOSS is currently unprofitable.
Growing Profit Margin: GOSS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GOSS is unprofitable, and losses have increased over the past 5 years at a rate of -64.4% per year.
Accelerating Growth: Unable to compare GOSS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GOSS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: GOSS has a negative Return on Equity (-65.84%), as it is currently unprofitable.
How is Gossamer Bio's financial position?
Financial Position Analysis
Short Term Liabilities: GOSS's short term assets ($355.4M) exceed its short term liabilities ($28.4M).
Long Term Liabilities: GOSS's short term assets ($355.4M) exceed its long term liabilities ($36.7M).
Debt to Equity History and Analysis
Debt Level: GOSS's debt to equity ratio (9.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GOSS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GOSS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GOSS has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 82.1% each year.
What is Gossamer Bio's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GOSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GOSS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GOSS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GOSS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GOSS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sheila Gujrathi (49yo)
Dr. Sheila K. Gujrathi, M.D., is the Co-Founder and President of Gossamer Bio, Inc. since October 2015 and has been its Chief Executive Officer since July 23, 2018. Dr. Gujrathi has been a Director of Goss ...
CEO Compensation Analysis
Compensation vs Market: Sheila's total compensation ($USD6.25M) is above average for companies of similar size in the US market ($USD3.13M).
Compensation vs Earnings: Sheila's compensation has been consistent with company performance over the past year.
|Co-Founder & Chairman||4.58yrs||US$1.55m||4.46% $42.2m|
|Chief Financial Officer||2yrs||US$2.65m||0.034% $324.2k|
|Chief Scientific Officer||1.75yrs||US$2.26m||0.16% $1.5m|
|Executive VP||2.75yrs||US$867.30k||0.70% $6.6m|
|Vice President of Human Resources||no data||no data||no data|
|Senior Vice President of Clinical Development||no data||no data||no data|
Experienced Management: GOSS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
|Co-Founder & Chairman||4.58yrs||US$1.55m||4.46% $42.2m|
|Independent Director||1.5yrs||US$337.44k||0.0095% $89.8k|
|Independent Director||2.33yrs||US$327.44k||0.050% $475.1k|
|Independent Director||2.33yrs||US$329.94k||no data|
|Independent Director||1.42yrs||US$334.94k||no data|
|Independent Director||1.42yrs||US$338.44k||no data|
Experienced Board: GOSS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15%.
Gossamer Bio, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Gossamer Bio, Inc.
- Ticker: GOSS
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$945.000m
- Shares outstanding: 75.78m
- Website: https://www.gossamerbio.com
Number of Employees
- Gossamer Bio, Inc.
- 3013 Science Park Road
- Suite 200
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GOSS||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 2019|
|4GB||MUN (Boerse Muenchen)||Yes||Common Stock||DE||EUR||Feb 2019|
|4GB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2019|
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/27 10:00|
|End of Day Share Price||2020/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.